Evofem Biosciences (EVFM) Competitors $0.01 +0.00 (+5.26%) As of 02:43 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. CPHI, SPRB, ONCO, INM, EVAX, OGEN, GLTO, CMND, PWUP, and BDRXShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include China Pharma (CPHI), Spruce Biosciences (SPRB), Onconetix (ONCO), InMed Pharmaceuticals (INM), Evaxion A/S (EVAX), Oragenics (OGEN), Galecto (GLTO), Clearmind Medicine (CMND), PowerUp Acquisition (PWUP), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors China Pharma Spruce Biosciences Onconetix InMed Pharmaceuticals Evaxion A/S Oragenics Galecto Clearmind Medicine PowerUp Acquisition Biodexa Pharmaceuticals Evofem Biosciences (NASDAQ:EVFM) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Do insiders & institutionals believe in EVFM or CPHI? 0.2% of Evofem Biosciences shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 17.3% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, EVFM or CPHI? Evofem Biosciences has higher revenue and earnings than China Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$11.39M0.10$52.98M-$0.07-0.14China Pharma$4.40M1.04-$3.08MN/AN/A Which has more volatility and risk, EVFM or CPHI? Evofem Biosciences has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Is EVFM or CPHI more profitable? Evofem Biosciences has a net margin of -46.42% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences-46.42% -91.97% -61.93% China Pharma -85.56%-63.93%-31.42% Does the media favor EVFM or CPHI? In the previous week, Evofem Biosciences had 2 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for Evofem Biosciences and 0 mentions for China Pharma. Evofem Biosciences' average media sentiment score of 0.49 beat China Pharma's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media. Company Overall Sentiment Evofem Biosciences Neutral China Pharma Neutral SummaryEvofem Biosciences beats China Pharma on 6 of the 11 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19M$852.40M$5.77B$9.78BDividend YieldN/A4.84%3.95%4.03%P/E Ratio-0.021.1222.3224.91Price / Sales0.1026.63467.21121.85Price / CashN/A19.5637.7659.36Price / Book0.006.7710.106.62Net Income$52.98M-$4.20M$3.26B$265.42M7 Day PerformanceN/A11.77%3.91%3.58%1 Month PerformanceN/A3.47%3.74%0.46%1 Year PerformanceN/A15.88%37.68%19.41% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences1.2545 of 5 stars$0.01+5.3%N/A+5.6%$1.19M$11.39M-0.02120News CoverageCPHIChina PharmaN/A$1.42-3.4%N/A-93.6%$4.63M$4.40M0.00250News CoverageSPRBSpruce Biosciences1.6912 of 5 stars$8.20-3.5%$131.25+1,500.6%-78.4%$4.61M$4.91M-8.7220Gap DownONCOOnconetix1.1012 of 5 stars$3.02+1.7%N/A-99.4%$4.59M$2.52M0.0012INMInMed Pharmaceuticals1.4194 of 5 stars$2.23-2.2%N/A-70.4%$4.57M$4.92M-0.1810EVAXEvaxion A/S2.5149 of 5 stars$3.21-1.2%$10.00+211.5%-79.8%$4.56M$3.34M-2.4360OGENOragenics0.1412 of 5 stars$1.12+1.8%N/A-96.3%$4.54MN/A-0.165GLTOGalecto3.7684 of 5 stars$3.40+1.8%$10.00+194.1%-75.6%$4.42MN/A-0.2640CMNDClearmind Medicine1.048 of 5 stars$1.02-1.0%N/A-26.8%$4.39MN/A-0.93N/APWUPPowerUp AcquisitionN/A$0.55+1.7%N/A-95.1%$4.24MN/A0.00N/AGap DownHigh Trading VolumeBDRXBiodexa Pharmaceuticals0.4206 of 5 stars$6.21-5.8%N/AN/A$4.08MN/A0.0020Gap DownHigh Trading Volume Related Companies and Tools Related Companies China Pharma Alternatives Spruce Biosciences Alternatives Onconetix Alternatives InMed Pharmaceuticals Alternatives Evaxion A/S Alternatives Oragenics Alternatives Galecto Alternatives Clearmind Medicine Alternatives PowerUp Acquisition Alternatives Biodexa Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access